Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs | Zendy

Thomas J. Hwang | Zendy; Nina Jain | Zendy; Julie C. Lauffenburger | Zendy; Kerstin Noëlle Vokinger | Zendy; Aaron S. Kesselheim | Zendy

Open Access

Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs

Author(s) -

Thomas J. Hwang,

Nina Jain,

Julie C. Lauffenburger,

Kerstin Noëlle Vokinger,

Aaron S. Kesselheim

Publication year - 2019

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2018.6417

Subject(s) - medicine , medicare part d , prescription drug , cost sharing , medical prescription , drug , drug prices , medicare part b , retrospective cohort study , cohort , pharmacy , emergency medicine , family medicine , pharmacology , finance , public economics , nursing , business , payment , economics

The US Department of Health and Human Services (HHS) has proposed to reform drug pricing in Medicare Part B, which primarily covers physician-administered drugs and biologic agents. One HHS proposal would shift coverage of certain drugs from Medicare Part B to Part D, which is administered by private prescription drug plans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research